Fresenius Medical Care AG & Co. (Pref) (ETR:FME) has been given a €83.00 ($97.65) price objective by equities researchers at Deutsche Bank AG in a research report issued on Friday. The firm currently has a “neutral” rating on the stock.

Other equities research analysts have also recently issued research reports about the company. UBS AG set a €68.00 ($80.00) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “sell” rating in a report on Friday, July 14th. Berenberg Bank set a €95.00 ($111.76) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Friday, June 30th. S&P Global set a €95.00 ($111.76) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Tuesday, August 1st. Commerzbank Ag set a €88.00 ($103.53) price target on Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Finally, J P Morgan Chase & Co set a €106.40 ($125.18) price target on Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research note on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of €88.35 ($103.94).

Shares of Fresenius Medical Care AG & Co. (FME) traded up 0.559% during mid-day trading on Friday, hitting €82.949. The company’s stock had a trading volume of 392 shares. The company has a market cap of €25.45 billion and a price-to-earnings ratio of 21.390. The company has a 50-day moving average of €81.54 and a 200 day moving average of €82.22. Fresenius Medical Care AG & Co. has a 1-year low of €70.82 and a 1-year high of €89.07.

ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/21/fresenius-medical-care-ag-83-00-by-deutsche-bank-ag.html.

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.